| Segment Reporting [Table Text Block] |
| | | As of March 31, 2026 | | As of December 31, 2025 | |
| | | Biopharma | | | CDMO | | | Consolidated | | | Biopharma | | | CDMO | | | Consolidated | |
| Cash and cash equivalents | | $ | 6,937 | | | $ | 278 | | | $ | 7,215 | | | $ | 12,277 | | | $ | 368 | | | $ | 12,645 | |
| Prepaid expenses and other current assets | | | 233 | | | | 454 | | | | 687 | | | | 156 | | | | 190 | | | | 346 | |
| Property and equipment, net | | | 30 | | | | 12,614 | | | | 12,644 | | | | 34 | | | | 12,607 | | | | 12,641 | |
| Deferred offering costs | | | 555 | | | | — | | | | 555 | | | | 136 | | | | — | | | | 136 | |
| Licensed technology, net | | | 2,993 | | | | — | | | | 2,993 | | | | 2,243 | | | | — | | | | 2,243 | |
| Operating lease right-of-use assets, net | | | — | | | | 10,086 | | | | 10,086 | | | | — | | | | — | | | | — | |
| Goodwill | | | — | | | | 3,457 | | | | 3,457 | | | | — | | | | 3,457 | | | | 3,457 | |
| Restricted cash | | | 368 | | | | — | | | | 368 | | | | — | | | | — | | | | — | |
| Other assets | | | 126 | | | | 84 | | | | 210 | | | | 124 | | | | — | | | | 124 | |
| Total consolidated assets of continuing operations | | $ | 11,242 | | | $ | 26,973 | | | $ | 38,215 | | | $ | 14,970 | | | $ | 16,622 | | | $ | 31,592 | |
| | | | Three Months Ended March 31, 2026 | | | | Three Months Ended March 31, 2025 | |
| | | Biopharma | | | CDMO | | | Consolidated | | | Biopharma | | | CDMO | | | Consolidated | |
| Operating Expenses | | | | | | | | | | | | | | | | | | | | | | | | |
| Research and development | | $ | 857 | | | $ | 997 | | | $ | 1,854 | | | $ | 335 | | | $ | — | | | $ | 335 | |
| Selling, general and administrative | | | 2,054 | | | | 1,726 | | | | 3,780 | | | | 1,042 | | | | — | | | | 1,042 | |
| Total operating expenses | | | 2,911 | | | | 2,723 | | | | 5,634 | | | | 1,377 | | | | — | | | | 1,377 | |
| Other expense (income) | | | | | | | | | | | | | | | | | | | | | | | | |
| Change in fair value of derivative liability | | | 33 | | | | — | | | | 33 | | | | — | | | | — | | | | — | |
| Interest income | | | 24 | | | | — | | | | 24 | | | | 4 | | | | — | | | | 4 | |
| Interest expense | | | (648 | ) | | | — | | | | (648 | ) | | | — | | | | — | | | | — | |
| Net other (expense) income | | | (591 | ) | | | — | | | | (591 | ) | | | 4 | | | | — | | | | 4 | |
| Net loss from operations before discontinued operations | | $ | (3,502 | ) | | $ | (2,723 | ) | | $ | (6,225 | ) | | $ | (1,373 | ) | | $ | — | | | $ | (1,373 | ) |
|